SGLT2 inhibitors in older adults: overcoming the age barrier

Srikanth Bellary, Anthony H Barnett

Research output: Contribution to journalLetter, comment/opinion or interviewpeer-review

Original languageEnglish
Pages (from-to)e127-e128
Number of pages2
JournalThe lancet. Healthy longevity
Issue number4
Publication statusPublished - Apr 2023

Bibliographical note

Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. This article refers to:
Pratley, Richard E. et al (2023) Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial. The Lancet Healthy Longevity, Volume 4, Issue 4, e143 - e154.


  • Aged
  • Hypoglycemic Agents - therapeutic use
  • Humans
  • Diabetes Mellitus, Type 2 - drug therapy
  • Sodium-Glucose Transporter 2 Inhibitors - therapeutic use

Cite this